[10-Q] ANGIODYNAMICS INC Quarterly Earnings Report
Filing Impact
Filing Sentiment
Form Type
10-Q
Rhea-AI Filing Summary
AngioDynamics Inc. reported first-quarter fiscal 2026 net sales of $75.7 million, up 12.2% from the prior-year quarter, driven by Med Tech growth of 26.1% (Auryon, NanoKnife, thrombus management) and modest Med Device growth of 2.3%. Gross margin rose 90 basis points to 55.3%. The company recorded a net loss of $10.9 million (loss per share $0.26), an improvement from a $12.8 million loss a year earlier.
The company continues restructuring actions with $2.3 million in charges this quarter and $25.6 million total recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum structure and ongoing minimum annual payments; $2.5 million was paid this quarter and a contingent $3.0 million may be due depending on the Federal Circuit appeal (oral argument set for October 8, 2025). Management maintains a valuation allowance on deferred tax assets and noted continued macroeconomic and supply-chain risks. The company has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025.
AngioDynamics Inc. ha riportato vendite nette del primo trimestre dell'esercizio 2026 di $75.7 milioni, in aumento del 12,2% rispetto al trimestre dell'anno precedente, trainato dalla crescita Med Tech del 26,1% (Auryon, NanoKnife, gestione del trombo) e da una modesta crescita Med Device del 2,3%. Il margine lordo è aumentato di 90 punti base fino al 55,3%. L'azienda ha registrato una perdita netta di $10,9 milioni (per azione $0,26), un miglioramento rispetto a una perdita di $12,8 milioni nello stesso periodo dell'anno precedente.
La società prosegue azioni di ristrutturazione con $2,3 milioni di oneri in questo trimestre e $25,6 milioni in totale registrati fino ad oggi. Un accordo con BD (Becton, Dickinson) comprende una struttura una tantum a forfait e pagamenti annuali minimi correnti; $2,5 milioni sono stati pagati in questo trimestre e un importo contingente di $3,0 milioni potrebbe essere dovuto a seconda del ricorso della Federal Circuit (udienza orale stabilita per 8 ottobre 2025). La direzione mantiene una svalutazione sulle attività fiscali differite e ha evidenziato rischi macroeconomici e di approvvigionamento continui. L'azienda dispone di una linea di credito revolving di $25,0 milioni con $0 utilizzato al 31 agosto 2025.
AngioDynamics Inc. reportó ventas netas del primer trimestre fiscal 2026 de $75.7 millones, un aumento del 12.2% respecto al trimestre del año anterior, impulsado por el crecimiento de Med Tech del 26.1% (Auryon, NanoKnife, manejo de trombos) y un modesto crecimiento de Med Device del 2.3%. El margen bruto subió 90 puntos base a 55.3%. La empresa registró una pérdida neta de $10.9 millones (pérdida por acción $0.26), una mejora respecto a una pérdida de $12.8 millones un año antes.
La empresa continúa con acciones de reestructuración con $2.3 millones en cargos este trimestre y $25.6 millones en total registrado hasta la fecha. Un acuerdo con BD (Becton, Dickinson) incluye una estructura única de suma global y pagos mínimos anuales continuos; $2.5 millones se pagaron este trimestre y un contingente $3.0 millones podría ser debido dependiendo de la apelación ante la Federal Circuit (audiencia oral programada para 8 de octubre de 2025). La gerencia mantiene una asignación de valoración en activos fiscales diferidos y señaló riesgos macroeconómicos y de cadena de suministro continuos. La empresa tiene una línea de crédito revolvente de $25.0 millones con $0 utilizado al 31 de agosto de 2025.
AngioDynamics Inc.의 2026 회계연도 1분기 순매출은 $75.7백만으로 전년 동분기 대비 12.2% 증가했으며, 이는 Med Tech 성장률이 26.1%를 기록한 덕분이고(Auryon, NanoKnife, 혈전 관리) Med Device의 성장도 2.3%으로 완만했다. 총이익률은 90bp포인트 상승하여 55.3%를 기록했다. 회사는 순손실 $10.9백만(주당 손실 $0.26)을 기록했고, 이는 전년 동기 손실 $12.8백만에서 개선된 것이다.
회사는 이번 분기에 $2.3백만의 비용과 지금까지 총 $25.6백만의 비용 구조 조치를 계속하고 있다. BD(Becton, Dickinson)와의 합의는 단일 일시 구조와 연간 최소 지불금을 포함하며; 이번 분기에 $2.5백만이 지급되었고 연방순회항소(Federal Circuit) 결정 여부에 따라 $3.0백만의 contingency가 있을 수 있다(구두 변론 예정일 2025년 10월 8일). 경영진은 이연법인세 자산에 대한 평가충당금을 유지하고 거시경제와 공급망 리스크가 지속됨에 주목했다. 회사의 가용 신용한도는 $25.0백만이며 2025년 8월 31일 현재 미인출 금액은 $0이다.
AngioDynamics Inc. a enregistré un chiffre d'affaires net du premier trimestre fiscal 2026 de $75,7 millions, en hausse de 12,2% par rapport au trimestre de l'année précédente, porté par la croissance Med Tech de 26,1% (Auryon, NanoKnife, gestion des thrombus) et une croissance modeste des Med Device de 2,3%. La marge brute a augmenté de 90 points de base pour atteindre 55,3%. La société a enregistré une perte nette de $10,9 millions (perte par action $0,26), en amélioration par rapport à une perte de $12,8 millions il y a un an.
La société poursuit des actions de restructuration avec $2,3 millions de charges ce trimestre et $25,6 millions au total enregistrés à ce jour. Un règlement avec BD (Becton, Dickinson) prévoit une structure forfaitaire unique et des paiements annuels minimums; $2,5 millions ont été versés ce trimestre et un montant éventuel de $3,0 millions pourrait être dû selon l'appel devant la Federal Circuit (audience orale fixée au 8 octobre 2025). La direction maintient une provision pour les actifs d'impôt différés et a souligné les risques macroéconomiques et d'approvisionnement continus. L'entreprise dispose d'une facilité de crédit renouvelable de $25,0 millions avec $0 utilisé au 31 août 2025.
AngioDynamics Inc. berichtete über den Nettoumsatz des ersten Quartals des Geschäftsjahres 2026 von $75,7 Millionen, was einem Anstieg von 12,2% gegenüber dem Vorjahresquartal entspricht und durch das Wachstum im Med Tech-Bereich von 26,1% (Auryon, NanoKnife, Thrombusmanagement) sowie ein moderates Wachstum im Med Device-Bereich von 2,3% getrieben wurde. Die Bruttomarge stieg um 90 Basispunkte auf 55,3%. Das Unternehmen verzeichnete einen Nettoloss von $10,9 Millionen (Verlust pro Aktie $0,26), eine Verbesserung gegenüber einem Verlust von $12,8 Millionen im Vorjahr.
Das Unternehmen setzt Restrukturierungsmaßnahmen fort, mit $2,3 Millionen an Aufwendungen in diesem Quartal und insgesamt $25,6 Millionen bislang ausgewiesen. Eine Einigung mit BD (Becton, Dickinson) umfasst eine einmalige Pauschalstruktur und fortlaufende jährliche Mindestzahlungen; $2,5 Millionen wurden in diesem Quartal gezahlt, und eine contingente $3,0 Millionen könnte je nach Ausgang des Federal Circuit-Verfahrens fällig werden (mündliche Verhandlung für 8. Oktober 2025 vorgesehen). Das Management behält eine Bewertung von latenten Steuern vor und wies auf anhaltende makroökonomische und Lieferkettenrisiken hin. Das Unternehmen verfügt über eine revolvierende Kreditlinie über $25,0 Millionen mit $0 Entnahmen zum 31. August 2025.
AngioDynamics Inc. أبلغت عن مبيعات صافية للربع الأول من العام المالي 2026 بلغت $75.7 مليون، بارتفاع 12.2% عن ربع السنة السابق، مدفوعاً بنمو Med Tech بنسبة 26.1% (Auryon، NanoKnife، إدارة التخثّر) وبنمو محدود في Med Device بنسبة 2.3%. ارتفع الهامش الإجمالي بمقدار 90 نقطة أساس ليصل إلى 55.3%. سجلت الشركة صافي خسارة قدرها $10.9 مليون (خسارة للسهم $0.26)، وهو تحسن من خسارة $12.8 مليون في السنة السابقة.
تواصل الشركة إجراءات إعادة الهيكلة مع $2.3 مليون من الرسوم في هذا الربع و$25.6 مليون إجمالياً حتى تاريخ اليوم. تشمل تسوية مع BD (Becton, Dickinson) بنية جمركية لمرة واحدة ومدفوعات سنوية حدّية مستمرة؛ تم دفع $2.5 مليون في هذا الربع وقد يستحق مبلغ تعويضي محتمل قدره $3.0 مليون وفقاً لاستئناف المحكمة الفدرالية (المرافعة الشفوية محددة لـ 8 أكتوبر 2025). تحتفظ الإدارة باحتياطي تقييم للأصول الضريبية المؤجلة وأشارت إلى مخاطر الاقتصاد الكلي وسلاسل الإمداد المستمرة. لدى الشركة تسهيل ائتماني دوراني بمقدار $25.0 مليون مع $0 مستدان حتى 31 أغسطس 2025.
AngioDynamics Inc. 公布2026财年第一季度净销售额为$75.7百万，较上年同期增长12.2%，受医疗技术增长26.1%（Auryon、NanoKnife、血栓管理）以及医疗设备的温和增长2.3%驱动。毛利率上升了90基点，达到55.3%。公司记录净亏损为$10.9百万（每股亏损$0.26），较上年同期的$12.8百万亏损有所改善。
公司继续进行重组行动，本季度涉及的费用为$2.3百万，迄今累计费用为$25.6百万。与BD（Becton, Dickinson） 的和解包含一次性总额结构与持续的最低年度支付；本季度已支付$2.5百万，且在联邦巡回法院上诉结果可能产生的对形势起决定作用的 contingents 为$3.0百万；听证日定于2025年10月8日。管理层对递延所得税资产维持评估减值准备，并指出宏观经济与供应链风险持续。公司拥有一条金额为$25.0百万的循环信贷额度，截至2025年8月31日未动用$0。
Positive
- Net sales increased 12.2% to $75.7M in Q1 FY2026
- Gross margin improved 90 basis points to 55.3%
- Med Tech revenue grew 26.1%, led by Auryon, NanoKnife and thrombus management
- $25.0M revolving credit facility available with $0 drawn as of August 31, 2025
- Net loss narrowed from $12.8M to $10.9M year-over-year
Negative
- Company remains unprofitable with a Q1 net loss of $10.9M
- $25.6M of total restructuring charges recorded to date, with ongoing actions
- Valuation allowance on deferred tax assets due to lack of sustained profitability
- 219 consolidated Port Product Claims pending, posing potential material exposure
- Settlement obligations to BD include recurring minimum payments and a contingent $3.0M payment tied to appeal outcome
Insights
Revenue growth and margin improvement, but continued losses and restructuring weigh on near-term profitability.
$75.7M in net sales (+12.2%) and a 55.3% gross margin show underlying product demand, led by Med Tech +26.1%. Operating performance improved as net loss narrowed to $10.9M, yet the company remains unprofitable and continues to record restructuring expenses totaling $25.6M.
The unused $25.0M revolver provides liquidity optionality, but management flagged supply-chain, inflation and labor pressures that could affect cash flow and margins.
Material legal settlement with BD and extensive product liability exposure remain key litigation risks.
The Settlement with BD required an initial lump sum and ongoing minimum payments; $2.5M minimum was paid this quarter and a contingent $3.0M may become due if the Federal Circuit reverses prior findings (oral argument Oct 8, 2025).
The company is defending approximately 219 Port Product Claims consolidated for pretrial proceedings, which the company notes could materially affect estimates if additional claims emerge or details change.
AngioDynamics Inc. ha riportato vendite nette del primo trimestre dell'esercizio 2026 di $75.7 milioni, in aumento del 12,2% rispetto al trimestre dell'anno precedente, trainato dalla crescita Med Tech del 26,1% (Auryon, NanoKnife, gestione del trombo) e da una modesta crescita Med Device del 2,3%. Il margine lordo è aumentato di 90 punti base fino al 55,3%. L'azienda ha registrato una perdita netta di $10,9 milioni (per azione $0,26), un miglioramento rispetto a una perdita di $12,8 milioni nello stesso periodo dell'anno precedente.
La società prosegue azioni di ristrutturazione con $2,3 milioni di oneri in questo trimestre e $25,6 milioni in totale registrati fino ad oggi. Un accordo con BD (Becton, Dickinson) comprende una struttura una tantum a forfait e pagamenti annuali minimi correnti; $2,5 milioni sono stati pagati in questo trimestre e un importo contingente di $3,0 milioni potrebbe essere dovuto a seconda del ricorso della Federal Circuit (udienza orale stabilita per 8 ottobre 2025). La direzione mantiene una svalutazione sulle attività fiscali differite e ha evidenziato rischi macroeconomici e di approvvigionamento continui. L'azienda dispone di una linea di credito revolving di $25,0 milioni con $0 utilizzato al 31 agosto 2025.
AngioDynamics Inc. reportó ventas netas del primer trimestre fiscal 2026 de $75.7 millones, un aumento del 12.2% respecto al trimestre del año anterior, impulsado por el crecimiento de Med Tech del 26.1% (Auryon, NanoKnife, manejo de trombos) y un modesto crecimiento de Med Device del 2.3%. El margen bruto subió 90 puntos base a 55.3%. La empresa registró una pérdida neta de $10.9 millones (pérdida por acción $0.26), una mejora respecto a una pérdida de $12.8 millones un año antes.
La empresa continúa con acciones de reestructuración con $2.3 millones en cargos este trimestre y $25.6 millones en total registrado hasta la fecha. Un acuerdo con BD (Becton, Dickinson) incluye una estructura única de suma global y pagos mínimos anuales continuos; $2.5 millones se pagaron este trimestre y un contingente $3.0 millones podría ser debido dependiendo de la apelación ante la Federal Circuit (audiencia oral programada para 8 de octubre de 2025). La gerencia mantiene una asignación de valoración en activos fiscales diferidos y señaló riesgos macroeconómicos y de cadena de suministro continuos. La empresa tiene una línea de crédito revolvente de $25.0 millones con $0 utilizado al 31 de agosto de 2025.
AngioDynamics Inc.의 2026 회계연도 1분기 순매출은 $75.7백만으로 전년 동분기 대비 12.2% 증가했으며, 이는 Med Tech 성장률이 26.1%를 기록한 덕분이고(Auryon, NanoKnife, 혈전 관리) Med Device의 성장도 2.3%으로 완만했다. 총이익률은 90bp포인트 상승하여 55.3%를 기록했다. 회사는 순손실 $10.9백만(주당 손실 $0.26)을 기록했고, 이는 전년 동기 손실 $12.8백만에서 개선된 것이다.
회사는 이번 분기에 $2.3백만의 비용과 지금까지 총 $25.6백만의 비용 구조 조치를 계속하고 있다. BD(Becton, Dickinson)와의 합의는 단일 일시 구조와 연간 최소 지불금을 포함하며; 이번 분기에 $2.5백만이 지급되었고 연방순회항소(Federal Circuit) 결정 여부에 따라 $3.0백만의 contingency가 있을 수 있다(구두 변론 예정일 2025년 10월 8일). 경영진은 이연법인세 자산에 대한 평가충당금을 유지하고 거시경제와 공급망 리스크가 지속됨에 주목했다. 회사의 가용 신용한도는 $25.0백만이며 2025년 8월 31일 현재 미인출 금액은 $0이다.
AngioDynamics Inc. a enregistré un chiffre d'affaires net du premier trimestre fiscal 2026 de $75,7 millions, en hausse de 12,2% par rapport au trimestre de l'année précédente, porté par la croissance Med Tech de 26,1% (Auryon, NanoKnife, gestion des thrombus) et une croissance modeste des Med Device de 2,3%. La marge brute a augmenté de 90 points de base pour atteindre 55,3%. La société a enregistré une perte nette de $10,9 millions (perte par action $0,26), en amélioration par rapport à une perte de $12,8 millions il y a un an.
La société poursuit des actions de restructuration avec $2,3 millions de charges ce trimestre et $25,6 millions au total enregistrés à ce jour. Un règlement avec BD (Becton, Dickinson) prévoit une structure forfaitaire unique et des paiements annuels minimums; $2,5 millions ont été versés ce trimestre et un montant éventuel de $3,0 millions pourrait être dû selon l'appel devant la Federal Circuit (audience orale fixée au 8 octobre 2025). La direction maintient une provision pour les actifs d'impôt différés et a souligné les risques macroéconomiques et d'approvisionnement continus. L'entreprise dispose d'une facilité de crédit renouvelable de $25,0 millions avec $0 utilisé au 31 août 2025.
AngioDynamics Inc. berichtete über den Nettoumsatz des ersten Quartals des Geschäftsjahres 2026 von $75,7 Millionen, was einem Anstieg von 12,2% gegenüber dem Vorjahresquartal entspricht und durch das Wachstum im Med Tech-Bereich von 26,1% (Auryon, NanoKnife, Thrombusmanagement) sowie ein moderates Wachstum im Med Device-Bereich von 2,3% getrieben wurde. Die Bruttomarge stieg um 90 Basispunkte auf 55,3%. Das Unternehmen verzeichnete einen Nettoloss von $10,9 Millionen (Verlust pro Aktie $0,26), eine Verbesserung gegenüber einem Verlust von $12,8 Millionen im Vorjahr.
Das Unternehmen setzt Restrukturierungsmaßnahmen fort, mit $2,3 Millionen an Aufwendungen in diesem Quartal und insgesamt $25,6 Millionen bislang ausgewiesen. Eine Einigung mit BD (Becton, Dickinson) umfasst eine einmalige Pauschalstruktur und fortlaufende jährliche Mindestzahlungen; $2,5 Millionen wurden in diesem Quartal gezahlt, und eine contingente $3,0 Millionen könnte je nach Ausgang des Federal Circuit-Verfahrens fällig werden (mündliche Verhandlung für 8. Oktober 2025 vorgesehen). Das Management behält eine Bewertung von latenten Steuern vor und wies auf anhaltende makroökonomische und Lieferkettenrisiken hin. Das Unternehmen verfügt über eine revolvierende Kreditlinie über $25,0 Millionen mit $0 Entnahmen zum 31. August 2025.
Table of Content
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended August 31, 2025
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from to
Commission file number 0-50761
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices and zip code)
(518 ) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||||||||||||
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
Table of Content
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer | ☐ | ☒ | ||||||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ||||||||||||||||||
| Emerging growth company | ||||||||||||||||||||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.
| Class | Outstanding as of October 1, 2025 | |||||||
| Common Stock, par value $.01 | ||||||||
Table of Content
AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
| Page | ||||||||
Part I: Financial Information | ||||||||
| Item 1. | Financial Statements | |||||||
Consolidated Statements of Operations (unaudited) | 3 | |||||||
Consolidated Statements of Comprehensive Loss (unaudited) | 4 | |||||||
Consolidated Balance Sheets (unaudited) | 5 | |||||||
Consolidated Statements of Cash Flows (unaudited) | 6 | |||||||
Consolidated Statements of Stockholders’ Equity (unaudited) | 7 | |||||||
Notes to Consolidated Financial Statements (unaudited) | 8 | |||||||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 | ||||||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 27 | ||||||
| Item 4. | Controls and Procedures | 28 | ||||||
Part II: Other Information | ||||||||
| Item 1. | Legal Proceedings | 29 | ||||||
| Item 1A. | Risk Factors | 29 | ||||||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29 | ||||||
| Item 3. | Defaults on Senior Securities | 29 | ||||||
| Item 4. | Mine Safety Disclosures | 29 | ||||||
| Item 5. | Other Information | 29 | ||||||
| Item 6. | Exhibits | 30 | ||||||
2
Table of Content
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)
| Three Months Ended | ||||||||||||||
| Aug 31, 2025 | Aug 31, 2024 | |||||||||||||
| Net sales | $ | $ | ||||||||||||
| Cost of sales (exclusive of intangible amortization) | ||||||||||||||
| Gross margin | ||||||||||||||
| Operating expenses: | ||||||||||||||
| Research and development | ||||||||||||||
| Sales and marketing | ||||||||||||||
| General and administrative | ||||||||||||||
| Amortization of intangibles | ||||||||||||||
| Change in fair value of contingent consideration | ||||||||||||||
| Acquisition, restructuring and other items, net | ||||||||||||||
| Total operating expenses | ||||||||||||||
| Operating loss | ( | ( | ||||||||||||
| Other expense: | ||||||||||||||
| Interest income (expense), net | ( | |||||||||||||
| Other expense, net | ( | ( | ||||||||||||
| Total other income (expense), net | ( | |||||||||||||
| Loss before income tax benefit | ( | ( | ||||||||||||
| Income tax expense | ||||||||||||||
| Net loss | $ | ( | $ | ( | ||||||||||
| Loss per share | ||||||||||||||
| Basic | $ | ( | $ | ( | ||||||||||
| Diluted | $ | ( | $ | ( | ||||||||||
| Weighted average shares outstanding | ||||||||||||||
| Basic | ||||||||||||||
| Diluted | ||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
3
Table of Content
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands of dollars)
| Three Months Ended | ||||||||||||||
| Aug 31, 2025 | Aug 31, 2024 | |||||||||||||
| Net loss | $ | ( | $ | ( | ||||||||||
| Other comprehensive income, before tax: | ||||||||||||||
| Foreign currency translation gain | ||||||||||||||
| Other comprehensive income, before tax | ||||||||||||||
| Income tax expense related to items of other comprehensive loss | ||||||||||||||
| Other comprehensive income, net of tax | ||||||||||||||
| Total comprehensive loss, net of tax | $ | ( | $ | ( | ||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
4
Table of Content
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
| Aug 31, 2025 | May 31, 2025 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
Accounts receivable, net of allowances of $ | |||||||||||
| Inventories | |||||||||||
| Prepaid expenses and other | |||||||||||
| Total current assets | |||||||||||
| Property, plant and equipment, net | |||||||||||
| Intangible assets, net | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| Liabilities and stockholders' equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | $ | |||||||||
| Accrued liabilities | |||||||||||
| Other current liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Deferred income taxes | |||||||||||
| Other long-term liabilities | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 14) | |||||||||||
| Stockholders' equity | |||||||||||
Preferred stock, par value $ | |||||||||||
Common stock, par value $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | ( | ( | |||||||||
Treasury stock, | ( | ( | |||||||||
| Accumulated other comprehensive income (loss) | ( | ||||||||||
| Total Stockholders’ Equity | |||||||||||
| Total Liabilities and Stockholders' Equity | $ | $ | |||||||||
The accompanying notes are an integral part of these consolidated financial statements.
5
Table of Content
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
The accompanying notes are an integral part of these consolidated financial statements.
| Three Months Ended | |||||||||||
| Aug 31, 2025 | Aug 31, 2024 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | ( | $ | ( | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation and amortization | |||||||||||
| Non-cash lease expense | |||||||||||
| Stock based compensation | |||||||||||
| Change in fair value of contingent consideration | |||||||||||
| Deferred income taxes | ( | ( | |||||||||
| Change in accounts receivable allowances | |||||||||||
| Fixed and intangible asset impairments and disposals | ( | ||||||||||
| Other | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | |||||||||||
| Inventories | ( | ( | |||||||||
| Prepaid expenses and other | ( | ( | |||||||||
| Accounts payable, accrued and other liabilities | ( | ( | |||||||||
| Net cash used in operating activities | ( | ( | |||||||||
| Cash flows from investing activities: | |||||||||||
| Additions to property, plant and equipment | ( | ( | |||||||||
| Additions to placement and evaluation units | ( | ( | |||||||||
| Net cash used in investing activities | ( | ( | |||||||||
| Cash flows from financing activities: | |||||||||||
| Principal payments on financing arrangement | ( | ||||||||||
| Repurchase of common stock | ( | ||||||||||
| Proceeds from exercise of stock options and employee stock purchase plan | |||||||||||
| Net cash provided by (used in) financing activities | ( | ||||||||||
| Effect of exchange rate changes on cash and cash equivalents | |||||||||||
| Decrease in cash and cash equivalents | ( | ( | |||||||||
| Cash and cash equivalents at beginning of period | |||||||||||
| Cash and cash equivalents at end of period | $ | $ | |||||||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||||||||
| Accrual for capital expenditures incurred during the period | $ | ( | $ | ( | |||||||
6
Table of Content
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)
| Common Stock | Additional paid in capital | Accumulated deficit | Accumulated other comprehensive income (loss) | Treasury Stock | |||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Total | |||||||||||||||||||||||||||||||||||||||||||
| Balance at May 31, 2025 | $ | $ | $ | ( | $ | ( | ( | $ | ( | $ | |||||||||||||||||||||||||||||||||||||
| Net loss | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Issuance/Cancellation of restricted stock units | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Purchases of common stock under ESPP | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at August 31, 2025 | $ | $ | $ | ( | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Common Stock | Additional paid in capital | Accumulated deficit | Accumulated other comprehensive loss | Treasury Stock | |||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Total | |||||||||||||||||||||||||||||||||||||||||||
| Balance at May 31, 2024 | $ | $ | $ | ( | $ | ( | ( | $ | ( | $ | |||||||||||||||||||||||||||||||||||||
| Net loss | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Issuance/Cancellation of restricted stock units | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Issuance/Cancellation of performance share units | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Purchases of common stock under ESPP | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | |||||||||||||||||||||||||||||||||||||||||||||||
| Common stock repurchased | ( | ( | $ | ( | ( | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance at August 31, 2024 | $ | $ | $ | ( | $ | ( | ( | $ | ( | $ | |||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
7
Table of Content
AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three months ended August 31, 2025 and 2024, the Consolidated Balance Sheet as of August 31, 2025, the Consolidated Statements of Cash Flows for the three months ended August 31, 2025 and 2024, and the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2025 and 2024 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2025 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2025 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three months ended August 31, 2025 and 2024 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.
2. REVENUE FROM CONTRACTS WITH CUSTOMERS
Revenue Recognition
Under ASC 606, Revenue from Contracts with Customers, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following table summarizes net sales by Med Tech, Med Device and by geography:
| Three Months Ended August 31, 2025 | Three Months Ended August 31, 2024 | ||||||||||||||||||||||||||||||||||
| (in thousands) | United States | International | Total | United States | International | Total | |||||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||||||||
| Med Tech | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
| Med Device | |||||||||||||||||||||||||||||||||||
| Total | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
Net Product Revenue
The Company's products consist of medical technology products focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
8
Table of Content
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposable revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, product returns, rebates and allowances that are offered within contracts between the Company and its customers. The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20 % restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. Discounts and product returns are based on amounts earned or to be claimed on the related sales and are classified as a contra asset. During the three months ended August 31, 2025 and 2024, such product returns were not material. The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in "Accrued liabilities" in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.
Contract Balances with Customers
A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in "Accrued liabilities" in the accompanying Consolidated Balance Sheets.
9
Table of Content
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
| (in thousands) | Aug 31, 2025 | May 31, 2025 | |||||||||
| Receivables | $ | $ | |||||||||
| Contract assets | $ | $ | |||||||||
| Contract liabilities | $ | $ | |||||||||
During the three months ended August 31, 2025, the Company had additions to contract liabilities of $0.1 million. This was offset by $0.1 million in revenue that was recognized during the three months ended August 31, 2025.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
3. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
| (in thousands) | Aug 31, 2025 | May 31, 2025 | |||||||||
| Raw materials | $ | $ | |||||||||
| Work in process | |||||||||||
| Finished goods | |||||||||||
| Inventories | $ | $ | |||||||||
4. INTANGIBLE ASSETS
Definite Lived Intangible Assets
Intangible assets are amortized over their estimated useful lives on a straight-line basis. Useful lives range from to eighteen years . The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
10
Table of Content
Intangible assets consisted of the following:
| Aug 31, 2025 | |||||||||||||||||
| (in thousands) | Gross carrying value | Accumulated amortization | Net carrying value | ||||||||||||||
| Product technologies | $ | $ | ( | $ | |||||||||||||
| Customer relationships | ( | ||||||||||||||||
| Trademarks | ( | ||||||||||||||||
| Licenses | ( | ||||||||||||||||
| $ | $ | ( | $ | ||||||||||||||
| May 31, 2025 | |||||||||||||||||
| (in thousands) | Gross carrying value | Accumulated amortization | Net carrying value | ||||||||||||||
| Product technologies | $ | $ | ( | $ | |||||||||||||
| Customer relationships | ( | ||||||||||||||||
| Trademarks | ( | ||||||||||||||||
| Licenses | ( | ||||||||||||||||
| $ | $ | ( | $ | ||||||||||||||
Amortization expense for the three months ended August 31, 2025 and 2024 was $2.7 million and $2.6 million, respectively.
Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:
| (in thousands) | |||||
| Remainder of 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 | |||||
| 2031 and thereafter | |||||
| $ | |||||
5. ACCRUED LIABILITIES
Accrued liabilities consisted of the following:
| (in thousands) | Aug 31, 2025 | May 31, 2025 | |||||||||
| Payroll and related expenses | $ | $ | |||||||||
| Outside services | |||||||||||
| Research and development | |||||||||||
| Royalties | |||||||||||
| Sales and franchise taxes | |||||||||||
| Deferred warranties | |||||||||||
| Transaction service agreement payable | |||||||||||
| Rebates | |||||||||||
| Accrued freight | |||||||||||
| Accrued severance | |||||||||||
| Other | |||||||||||
| $ | $ | ||||||||||
11
Table of Content
6. LONG-TERM DEBT
On May 28, 2025, the Company entered into a new Credit Agreement (the “Credit Agreement”) with its subsidiary RITA Medical Systems, LLC (“RITA” and, together with the Company, the “Loan Parties”), the lenders party thereto and JPMorgan Chase Bank, N.A., individually and as administrative agent, issuing bank and swingline lender.
The Credit Agreement provides for a $25.0 million secured revolving credit facility (the "Revolving Facility"), which is subject to a borrowing base comprised of certain working capital assets of the Company. Additionally, until such time as the Company has demonstrated a fixed charge coverage ratio greater than 1.10 to 1.00, the Revolving Facility will be further reduced by $5,000,000 (such period, the “Availability Block Period”). To the extent requested by the Company, and subject to certain customary limitations, the lenders will make revolving loan advances to the Company and the issuing bank will issue letters of credit for the account of the Company, in each case in an aggregate amount not exceeding the availability under the Revolving Facility. Issuances of letters of credit under the Revolving Facility shall further be limited by an issuance cap, which at the closing date was set at $2,000,000 . The proceeds of the Revolving Facility may be used for working capital and for general corporate needs of AngioDynamics and its subsidiaries.
The Credit Agreement has a two-year maturity. Interest on the Revolving Facility will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.1 % (subject to a floor of 0 %) ("Adjusted Term SOFR"), or (ii) the alternate base rate (subject to a floor of 0 %) ("ABR"), and in each case with a margin for Adjusted Term SOFR loans of 2.0 % and for ABR loans of 1.0 %. The Revolving Facility will also carry a commitment fee of 0.2 % per annum on the unused portion. The Revolving Facility contains customary benchmark replacement and rate fallback provisions.
The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). The sole Guarantor as at the closing date is RITA. All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Loan Parties and the Guarantors.
The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, a financial covenant which requires the Company to maintain, as of the end of each calendar month commencing after the end of the Availability Block Period, a fixed charge coverage ratio of EBITDA* minus unfinanced capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.05 to 1.00.
* The definitions of total indebtedness, EBITDA, capital expenditures and interest expense are specifically defined in the Credit Agreement included as an exhibit to Form 8-K filed on May 28, 2025.
7. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was (0.6 )% as of the first quarter of fiscal year 2026, as compared to 1.8 % for the same period in fiscal year 2025. In fiscal year 2026, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state Research and Development ("R&D") credit carryforwards and other net deferred tax assets as of August 31, 2025. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest
12
Table of Content
expense limitation. In accordance with ASC 740, the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. deferred tax assets, the legislation does not have a material impact on our consolidated financial statements for the quarter ended August 31, 2025.
8. SHARE-BASED COMPENSATION
On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 12, 2024 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 3.2 million shares. As of August 31, 2025, there was a maximum of 2.5 million shares of common stock available for future grant under the 2020 Plan.
Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.
The Company also has an employee stock purchase plan. As of August 31, 2025, there was a maximum of 2.5 million shares of common stock available for future grant under the employee stock purchase plan.
For the three months ended August 31, 2025 and 2024, share-based compensation expense was $4.5 million and $3.2 million, respectively.
During the three months ended August 31, 2025 and 2024, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Generally, restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. In July 2023, the Board of Directors approved a change in terms of restricted stock units granted to non-employee directors to provide for immediate vesting upon grant of the award.
During the three months ended August 31, 2025 and 2024, the Company granted performance share units under the 2020 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards is based on a Monte Carlo simulation model.
9. EQUITY
10. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
13
Table of Content
The following table reconciles basic to diluted weighted-average shares outstanding:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Basic | |||||||||||
| Effect of dilutive securities | |||||||||||
| Diluted | |||||||||||
| Securities excluded as their inclusion would be anti-dilutive | |||||||||||
11. SEGMENT AND GEOGRAPHIC INFORMATION
Segment information
The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), to evaluate performance and allocate resources. The Company manages its operations through two operating segments, Med Tech and Med Device. The CEO evaluates these two operating segments based on gross margin to, among other items, allocate resources and assess performance. The CEO uses gross margin in the budgeting and forecasting process to assess profitability and enable decision making regarding strategic initiatives, investments and personnel across the two operating segments. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions.
The Med Tech segment is comprised of our technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment is comprised of our Core, Venous, Ports and other Oncology products.
The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment.
The table below summarizes net sales, cost of sales and gross margin by Med Tech and Med Device:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Med Tech Net Sales | $ | $ | |||||||||
| Med Tech Cost of Sales (exclusive of intangible amortization) | |||||||||||
| Gross Margin | |||||||||||
| Gross Margin % | % | % | |||||||||
| Med Device Net Sales | $ | $ | |||||||||
| Med Device Cost of Sales (exclusive of intangible amortization) | |||||||||||
| Gross Margin | |||||||||||
| Gross Margin % | % | % | |||||||||
| Total Net Sales | $ | $ | |||||||||
| Total Cost of Sales (exclusive of intangible amortization) | |||||||||||
| Gross Margin | |||||||||||
| Gross Margin % | % | % | |||||||||
Operating Expenses(1) | $ | $ | |||||||||
Other income (expense), net(2) | ( | ||||||||||
| Loss before income tax benefit | ( | ( | |||||||||
14
Table of Content
(1) Operating expenses include Research and development, Sales and marketing, General and administrative, Amortization of intangibles, Change in fair value of contingent consideration and Acquisition, restructuring and other items, net.
(2) Other income (expense), net includes interest income, interest expense, foreign currency impacts and bank fees.
Geographic information
The table below summarizes net sales by geographic area based on external customer location:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Net Sales | |||||||||||
| United States | $ | $ | |||||||||
| International | |||||||||||
| Total | $ | $ | |||||||||
12. FAIR VALUE
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
The Company's financial instruments include cash and cash equivalents, accounts receivable and accounts payable. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The Company does not have assets or liabilities that require recurring fair value measurement using significant unobservable inputs (Level 3).
13. LEASES
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. The Company has financing arrangement for manufacturing and distribution.
Financing Arrangement
On December 24, 2024, the Company entered into an agreement to sell the manufacturing facilities in Queensbury, NY and Glens Falls, NY for a purchase price of $5.5 million and $1.2 million, respectively, and net proceeds of $5.2 million and $1.1 million, respectively. The Company simultaneously entered into lease agreements with future lease payments of $4.6 million over seven years for the Queensbury, NY facility and $0.4 million over three years for the Glens Falls, NY facility.
Based on certain criteria, the transaction was accounted for as a financing arrangement, as it did not meet the criteria for a sale-leaseback. As a result, the assets remain in "Property, plant and equipment, net" on the Consolidated Balance Sheets at their historical book value and are depreciated over the term of the lease agreements. A financing arrangement was recorded in the amount of the net proceeds received. The Company will recognize monthly rent as a reduction of the finance arrangement
15
Table of Content
and interest expense, using the effective interest rate method. No gain or loss was recognized related to the financing arrangement for the three months ended August 31, 2025.
As of August 31, 2025, the carrying value of the financing arrangement was $6.1 million, of which $0.4 million was classified as "Other current liabilities" and $5.7 million was classified as "Other long-term liabilities" on the Consolidated Balance Sheets. Interest expense associated with the financing arrangement was $0.1 million for the three months ending August 31, 2025.
Remaining future cash payments related to the financing arrangement as of August 31, 2025 for each of the following fiscal years is:
| (in thousands) | Aug 31, 2025 | ||||
| Remainder of 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 and thereafter | |||||
| Total minimum liability payments | $ | ||||
| Less: imputed interest | ( | ||||
| Total | $ | ||||
Operating Leases
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
The following table presents supplemental balance sheet information related to leases:
| (in thousands) | Balance Sheet Location | Aug 31, 2025 | May 31, 2025 | ||||||||||||||
| Assets | |||||||||||||||||
| Operating lease ROU asset | $ | $ | |||||||||||||||
| Liabilities | |||||||||||||||||
| Current operating lease liabilities | |||||||||||||||||
| Non-current operating lease liabilities | |||||||||||||||||
| Total lease liabilities | $ | $ | |||||||||||||||
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
| Aug 31, 2025 | |||||
| Weighted average remaining term (in years) | |||||
| Weighted average discount rate | % | ||||
16
Table of Content
The maturities of the lease liabilities for each of the following fiscal years is:
| (in thousands) | Aug 31, 2025 | ||||
| Remainder of 2026 | $ | ||||
| 2027 | |||||
| 2028 | |||||
| 2029 | |||||
| 2030 and thereafter | |||||
| Total lease payments | $ | ||||
| Less: imputed interest | |||||
| Total lease obligations | $ | ||||
| Less: Current portion of lease obligations | |||||
| Long-term lease obligations | $ | ||||
During the three months ended August 31, 2025 and 2024, the Company recognized $0.6 million and $0.7 million of operating lease expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Cost of sales | $ | $ | |||||||||
| Research and development | |||||||||||
| Sales and marketing | |||||||||||
| General and administrative | |||||||||||
| Acquisition, restructuring and other items, net | |||||||||||
| $ | $ | ||||||||||
The following table presents supplemental cash flow and other information related to leases:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Cash paid for amounts included in the measurement of lease liabilities | |||||||||||
| Operating cash flows from operating leases | $ | $ | |||||||||
| ROU assets obtained in exchange for lease liabilities | |||||||||||
| Operating leases | $ | $ | |||||||||
14. COMMITMENTS AND CONTINGENCIES
The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
C.R. Bard, Inc. v. AngioDynamics, Inc.
On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")).
On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The Court entered Judgement on June 1, 2023 in favor of the Company.
17
Table of Content
On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993. The Company counterclaimed, alleging that certain of Bard’s catheter products infringe U.S. Patent Nos. 8,377,011, 10,729,881, 8,454,574.
On March 31, 2024, the Company and Bard’s parent company Becton, Dickinson and Company (collectively, “BD”) entered into a settlement agreement (the “Settlement Agreement”) to resolve the ongoing litigations. Under the terms of the Settlement Agreement, BD granted a license to the Company under certain of BD’s port patents and AngioDynamics granted BD a license under certain of the Company’s catheter patents. The Company made a one-time lump sum payment to BD in the amount of $7.0 million, $3.0 million which was paid within 5 business days of execution of the Settlement Agreement, and the remainder is payable in installments during 12 month period ending March 31, 2025. The Company will also make six minimum annual payments to BD of $2.5 million starting in fiscal year 2025, and potential additional payments if six percent (6 %) of annual net sales of the Company’s port products exceed the minimum payment. The Company made payments of $2.5 million related to the minimum annual payments to BD during the quarter ended August 31, 2025. The parties will participate in the pending appeal before the Federal Circuit of the case that was filed March 10, 2015 and a contingent payment of $3.0 million will be due from the Company to BD if the Federal Circuit reverses or vacates the District Court’s findings of invalidity with respect to the patent claims at issue in the case. Oral argument in the appeal will take place on October 8, 2025. Neither party admitted any liability and the agreement contains mutual covenants not to sue and releases. As of August 31, 2025, there was $2.4 million payable to BD recorded in other current liabilities and $6.7 million recorded in other long-term liabilities.
Port Product Claims
15. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET
Acquisition, Restructuring and Other Items
Acquisition, restructuring and other items, net, consisted of:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
Legal (1) | $ | $ | |||||||||
Plant closure (2) | |||||||||||
Transition service agreement (3) | ( | ( | |||||||||
| Other | |||||||||||
| Total | $ | $ | |||||||||
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.
(3) Transition services agreements that were entered into with Merit and Spectrum.
Restructuring
The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations. On January 5, 2024, the Company announced a restructuring to optimize its manufacturing efficiency, capabilities and footprint (the "Plan").
In the second quarter of fiscal year 2025, the Company announced a modification to the Plan to maintain a presence in Queensbury, NY for the manufacturing of select products, customer service, logistics, shipping, quality and regulatory operations. The restructuring activities associated with the modified Plan are still expected to be completed in the third quarter of fiscal year 2026.
18
Table of Content
The following table provides a summary of our estimated costs associated with the plan:
| Type of cost (in thousands) | Total original estimated amount expected to be incurred | Total modified estimated amount expected to be incurred | |||||||||||||||||||||
Facilities closeout fees (1) | $ | to | $ | $ | to | $ | |||||||||||||||||
| Termination benefits | to | to | |||||||||||||||||||||
| Outside consultants | to | to | |||||||||||||||||||||
| Validation expenses | to | to | |||||||||||||||||||||
| Regulatory filings | to | to | |||||||||||||||||||||
| Other | to | to | |||||||||||||||||||||
| $ | to | $ | $ | to | $ | ||||||||||||||||||
(1) Included in the original and modified estimate is approximately $13.6 million and $13.3 million of non-cash charges for accelerated depreciation and building impairment.
The Company recorded restructuring charges related to the plan during the three months ended August 31, 2025 of $2.3 million. Total restructuring charges recorded to date are $25.6 million. Termination benefits are only earned if an employee stays until their termination date; therefore, the expenses related to termination benefits are being recorded ratably over the service period.
The table below presents the restructuring reserve:
Three Months Ended Aug 31, 2025 | |||||||||||||||||||||||||||||||||||||||||
| Termination Benefits | Outside Consultants | Validation Expenses | Facilities Closeout Fees | Regulatory Filings | Other | Total | |||||||||||||||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||||||||||||||||||||
| Balance at May 31, 2025 | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
| Charges | |||||||||||||||||||||||||||||||||||||||||
| Non-cash adjustments | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Cash payments | ( | ( | ( | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Balance at August 31, 2025 | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
16. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Pronouncements - Adopted
There are no recently issued accounting pronouncements that have been adopted.
19
Table of Content
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
| Standard | Description | Effective Date | Effect on the Consolidated Financial Statements | ||||||||
ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures | This ASU improves the income tax disclosure requirements on an annual basis by (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. | June 1, 2025 | The Company plans to adopt the new standard for the fiscal year 2026 Annual Report on Form 10-K and is assessing the impact to the consolidated financial statements. | ||||||||
ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-04): Disaggregation of Income Statement Expenses | This ASU improves the disclosures about a public business entity's costs and expenses by requiring the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) included in each relevant income statement caption. | June 1, 2027 | The Company plans to adopt the new standard for the fiscal year 2028 and is assessing the impact to the consolidated financial statements. | ||||||||
ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets | This ASU addresses challenges encountered when applying the guidance to current account receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers. | June 1, 2026 | The Company plans to adopt the new standard for the fiscal year 2027 and is assessing the impact to the consolidated financial statements. | ||||||||
There have been no material changes to our critical accounting policies since our Annual Report on Form 10-K for fiscal year ended May 31, 2025.
20
Table of Content
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q. The following discussion should be read in conjunction with the Company's 2025 Annual Report on Form 10-K, and the consolidated financial statements and notes thereto included elsewhere in the Form 10-Q.
Disclosure Regarding Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics disclaims any obligation to update the forward-looking statements.
Disclosure Regarding Trademarks
This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP. Information on our website or connected to our website is not incorporated by reference into this Quarterly Report on Form 10-Q.
Executive Overview
AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.
21
Table of Content
Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical devices; and fluctuations in the global economy.
Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities.
We sell our products in the United States primarily through a direct sales force, and outside the U.S. mainly through distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.
The current macroeconomic environment continues to impact our business and may continue to pose future risks. The Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog, inflation (including the cost and availability of raw materials, direct labor and shipping) and tariffs have impacted our business, trends that may continue. Accordingly, management continues to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance.
In evaluating the operating performance of our business, management focuses on company-wide and segment revenue and gross margin and company-wide operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three months ended August 31, 2025 compared to the three months ended August 31, 2024 are as follows:
Three months ended August 31, 2025:
•Revenue increased by 12.2% to $75.7 million
•Med Tech and Med Device growth of 26.1% and 2.3%, respectively
•Gross margin increased 90 bps to 55.3%
•Med Tech gross margin decreased 110 bps to 62.2% and Med Device gross margin increased 120 bps to 49.3%
•Net loss decreased by $1.9 million to $10.9 million
•Loss per share decreased by $0.05 to $0.26
Our Med Tech revenue, comprised of Auryon, the thrombus management platform and NanoKnife, grew 26.1% in the first quarter of fiscal year 2026 driven by Auryon, NanoKnife and the thrombus management products. Our Med Device revenue grew by 2.3% in the first quarter of fiscal year 2026 driven by growth in the Core and Venous product lines which was partially offset by softness in the Ports and Microwave product lines.
Results of Operations
For the three months ended August 31, 2025, the Company reported net loss of $10.9 million, or diluted loss per share of $0.26, on net sales of $75.7 million, compared with a net loss of $12.8 million, or diluted loss per share of $0.31, on net sales of $67.5 million during the same quarter of the prior year.
Net sales - Net sales are derived from the sale of products and related freight charges, less discounts, rebates and returns.
| Three Months Ended | |||||||||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | $ Change | ||||||||||||||
| Net Sales | |||||||||||||||||
| Med Tech | $ | 35,261 | $ | 27,969 | $ | 7,292 | |||||||||||
| Med Device | 40,450 | 39,522 | $ | 928 | |||||||||||||
| Total | $ | 75,711 | $ | 67,491 | $ | 8,220 | |||||||||||
22
Table of Content
| Three Months Ended | |||||||||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | $ Change | ||||||||||||||
| Net Sales | |||||||||||||||||
| United States | $ | 66,456 | $ | 59,481 | $ | 6,975 | |||||||||||
| International | 9,255 | 8,010 | $ | 1,245 | |||||||||||||
| Total | $ | 75,711 | $ | 67,491 | $ | 8,220 | |||||||||||
For the three months ended August 31, 2025, net sales increased $8.2 million to $75.7 million compared to the same period in the prior year. At August 31, 2025, the Company had a backlog of $0.4 million.
The Med Tech segment net sales increased $7.3 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change in sales from the prior year was primarily driven by:
•Increased Auryon sales of $2.7 million;
•Increased sales of the thrombus management platform of $3.2 million, which was driven by an increase in AngioVac and AlphaVac sales of $3.3 million and was partially offset by a decrease in thrombolytic sales of $0.1 million; and
•Increased NanoKnife sales of $1.4 million, which was driven by increased disposable sales.
The Med Device segment net sales increased $0.9 million for the three months ended August 31, 2025 compared to the same period in the prior year. The backlog, which primarily impacted sales of Core products, was $0.4 million. The change in sales from the prior year was primarily driven by:
•Increased sales of Venous, Core and Oncology products of $0.7 million, $1.0 million and $0.2 million, respectively, which was partially offset by decreased sales of Ports and Microwave of $0.7 million and $0.2 million, respectively.
Gross Margin
| Three Months Ended | |||||||||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | $ Change | ||||||||||||||
| Med Tech | $ | 21,922 | $ | 17,697 | $ | 4,225 | |||||||||||
| Gross margin % of sales | 62.2 | % | 63.3 | % | |||||||||||||
| Med Device | $ | 19,935 | $ | 19,027 | $ | 908 | |||||||||||
| Gross margin % of sales | 49.3 | % | 48.1 | % | |||||||||||||
| Total | $ | 41,857 | $ | 36,724 | $ | 5,133 | |||||||||||
| Gross margin % of sales | 55.3 | % | 54.4 | % | |||||||||||||
Gross margin - Gross margin consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.
Total Company gross margin increased by $5.1 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Sales volume, price and product mix, which positively impacted gross margin by $6.6 million;
•Benefits from product lines transitioned to third-party manufacturing, which positively impacted gross margin by $0.7 million;
•Productivity and other incentives, which positively impacted gross margin $0.3 million;
•Tariffs, which negatively impacted gross margin by $1.7 million;
•Production volume, which negatively impacted gross margin by $0.3 million; and
•Incremental depreciation on placement units of $0.6 million.
The Med Tech segment gross margin increased by $4.2 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Sales volume, production volume and price, which positively impacted gross margin by $6.5 million;
•Tariffs, which negatively impacted gross margin by $0.5 million;
23
Table of Content
•Product mix and other incentives, which negatively impacted gross margin by $1.0 million; and
•Incremental depreciation on placement units of $0.7 million.
The Med Device segment gross margin increased by $0.9 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Price and product mix, which positively impacted gross margin by $2.0 million;
•Benefits from product lines transitioned to third-party manufacturing, which positively impacted gross margin by $0.7 million;
•Productivity and other incentives, which positively impacted gross margin by $0.3 million;
•Tariffs, which negatively impacted gross margin by $1.1 million;
•Sales volume and production volume, which negatively impacted gross margin by $1.1 million; and
•A decrease in incremental depreciation on placement units of $0.2 million.
Operating Expenses and Other Income (Expense)
| Three Months Ended | |||||||||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | $ Change | ||||||||||||||
| Research and development | $ | 6,417 | $ | 6,285 | $ | 132 | |||||||||||
| % of sales | 8.5 | % | 9.3 | % | |||||||||||||
| Selling and marketing | $ | 28,130 | $ | 25,605 | $ | 2,525 | |||||||||||
| % of sales | 37.2 | % | 37.9 | % | |||||||||||||
| General and administrative | $ | 12,555 | $ | 10,975 | $ | 1,580 | |||||||||||
| % of sales | 16.6 | % | 16.3 | % | |||||||||||||
Research and development expense - R&D expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.
R&D expense increased $0.1 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Compensation and benefits expenses, which increased $0.1 million.
Sales and marketing expense - Sales and marketing (“S&M”) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.
S&M expense increased $2.5 million for the three months ending August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Compensation and benefits expense, which increased by $1.8 million;
•Consulting and other selling expenses, which increased $0.6 million; and
•Trade shows, subscriptions and other marketing expenses, which increased $0.1 million.
General and administrative expense - General and administrative (“G&A”) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.
G&A expense increased $1.6 million for the three months ended August 31, 2025 compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Compensation and benefits expenses, which increased $2.3 million;
•Other outside consultant spend, which decreased $0.3 million; and
•Depreciation and other corporate expenses, which decreased $0.4 million.
24
Table of Content
| Three Months Ended | |||||||||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | $ Change | ||||||||||||||
| Amortization of intangibles | $ | 2,653 | $ | 2,570 | $ | 83 | |||||||||||
| Change in fair value of contingent consideration | $ | — | $ | 76 | $ | (76) | |||||||||||
| Acquisition, restructuring and other items, net | $ | 2,758 | $ | 4,311 | $ | (1,553) | |||||||||||
| Other expense, net | $ | (182) | $ | 433 | $ | (615) | |||||||||||
Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.
•Amortization expense remained consistent with the same period in the prior year.
Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.
•The change in the fair value for the three months ended August 31, 2025 is related to the Eximo contingent consideration. The final milestone associated with the contingent consideration was reached during the third quarter of fiscal year 2025 and was paid during the fourth quarter of fiscal year 2025.
Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.
Acquisition, restructuring and other items, net, decreased by $1.6 million for the three months ended August 31, 2025, compared to the same period in the prior year. The change from the prior year was primarily driven by:
•Legal expense, related to litigation that is outside of the normal course of business, which decreased $0.3 million;
•Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024, which decreased $1.2 million;
•Transaction services agreements that were entered into as a result of the divestiture of the PICCs, Midline, dialysis and BioSentry businesses. The decrease in the fees invoiced was $0.2 million; and
•Other expenses, mainly severance associated with organizational changes, which decreased $0.2 million.
Other expense, net - Other expenses include interest expense, foreign currency impacts and bank fees.
•The change in other expense of $0.6 million for the three months ended August 31, 2025, compared to the same period in the prior year, is primarily due to decreased interest income of $0.6 million.
Income Tax Benefit
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Income tax benefit | $ | 0.1 | $ | 0.1 | |||||||
| Effective tax rate including discrete items | (0.6) | % | (1.1) | % | |||||||
Our effective tax rate including discrete items for the three months ended August 31, 2025 and August 31, 2024 was (0.6)% and (1.1)%, respectively. In fiscal year 2026, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock-based compensation).
Liquidity and Capital Resources
We regularly review our liquidity and anticipated capital requirements and we believe that our current cash on hand provides sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months.
Our cash and cash equivalents totaled $38.8 million as of August 31, 2025, compared with $55.9 million as of May 31, 2025. As of August 31, 2025 and May 31, 2025 the Company did not have any outstanding debt.
25
Table of Content
The table below summarizes our cash flows:
| Three Months Ended | |||||||||||
| (in thousands) | Aug 31, 2025 | Aug 31, 2024 | |||||||||
| Cash provided by (used in): | |||||||||||
| Operating activities | $ | (15,914) | $ | (18,253) | |||||||
| Investing activities | (1,551) | (2,405) | |||||||||
| Financing activities | 143 | (509) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | 191 | 116 | |||||||||
| Net change in cash and cash equivalents | $ | (17,131) | $ | (21,051) | |||||||
During the quarters ended August 31, 2025 and 2024, cash flows consisted of the following:
Cash used in operating activities
Three months ended August 31, 2025 and 2024:
•Net loss of $10.9 million and $12.8 million, respectively, plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, along with the changes in working capital below, contributed to cash used in operations of $15.9 million and $18.3 million, respectively, for these periods.
•For the period ended August 31, 2025, working capital was unfavorably impacted by decreased accounts payable, accrued liabilities and other liabilities of $10.7 million, along with increased inventory and prepaid expenses of $0.2 million and $5.5 million, respectively. This was partially offset by decreased accounts receivable of $0.1 million.
•For the period ended August 31, 2024, working capital was unfavorably impacted by decreased accounts payable, accrued liabilities and other liabilities of $15.0 million, along with increased inventory and prepaid expenses of $4.1 million and $0.8 million, respectively. This was partially offset by decreased accounts receivable of $3.8 million.
Cash used in investing activities
Three months ended August 31, 2025 and 2024:
•$0.7 million and $1.1 million, respectively, of cash was used for fixed asset additions; and
•$0.8 million and $1.3 million, respectively, of cash was used for Auryon placement and evaluation unit additions.
Cash provided by (used in) financing activities
Three months ended August 31, 2025 and 2024:
•$0.1 million of principal payments on the financing arrangements in the first quarter of fiscal year 2026;
•$0.2 million of proceeds from stock option and ESPP activity in the first quarter of fiscal year 2026; and
•$0.6 million of cash was used for the repurchase of commons shares in the first quarter of fiscal year 2025.
We believe that our current cash balance, together with cash generated from operations and the Revolving Facility will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing.
New Accounting Pronouncements
Information regarding new accounting pronouncements is included in Note 16 to our consolidated financial statements in this Quarterly Report on Form 10-Q.
26
Table of Content
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Foreign Currency Exchange Rate Risk
We are exposed to market risk from changes in currency exchange rates and investments that could impact our results of operations and financial position.
We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British Pound and Canadian Dollar. For the three months ended August 31, 2025, approximately 3.2% of our sales were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross margin will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.
Interest Rate Risk
The risk associated with fluctuating interest rates is primarily limited to indebtedness. As of August 31, 2025, the Company did not have any outstanding debt (see Note 6, "Long-Term Debt" set forth in the Notes in the consolidated financial statements included in this Annual Report on Form 10-K).
The Credit Agreement provides for a $25.0 million secured revolving credit facility. Interest on the Revolving Facility will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.1% (subject to a floor of 0%) ("Adjusted Term SOFR"), or (ii) the alternate base rate (subject to a floor of 0%) ("ABR"), and in each case with a margin for Adjusted Term SOFR loans of 2.0% and for ABR loans of 1.0%. The Revolving Facility will also carry a commitment fee of 0.2% per annum. As of August 31, 2025 there were no amounts outstanding on the Revolving Facility.
Concentration of Credit Risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and trade accounts receivable.
The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness.
Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.
27
Table of Content
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting for the fiscal quarter ended August 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
28
Table of Content
AngioDynamics, Inc. and Subsidiaries
PART II: OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 14 "Commitments and Contingencies" set forth in the notes to our consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2025 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table provides information with respect to the shares of the Company’s common stock repurchased during the three months ended August 31, 2025:
| Issuer Purchases of Equity Securities | |||||||||||||||||||||||
| Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs (2) | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs (2) | ||||||||||||||||||||
| June 1, 2025 - June 30, 2025 | 1,400 | $ | 10.47 | — | $ | — | |||||||||||||||||
| July 1, 2025 - July 31, 2025 | 53,006 | $ | 9.15 | — | $ | — | |||||||||||||||||
| August 1, 2025 - August 31, 2025 | — | $ | 9.06 | — | $ | — | |||||||||||||||||
| Total | 54,406 | $ | 9.19 | — | — | ||||||||||||||||||
(1)These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares/units from equity-based awards.
(2)The Repurchase Program that was approved by the Board of Directors and announced on July 16, 2024 permits the Company to repurchase up to $15.0 million of its outstanding common stock. The timing and amount of any share repurchases under the authorization will be determined by management within certain parameters and based on market conditions and other considerations.
Item 3. Defaults on Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
Insider Trading Arrangements
During the quarter ended August 31, 2025, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) or the Company adopted terminated
29
Table of Content
Item 6
| EXHIBIT INDEX | Incorporated by Reference | |||||||||||||
| No. | Description | Form | Exhibit | Filing Date | ||||||||||
| 31.1 | Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934 | |||||||||||||
| 31.2 | Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934 | |||||||||||||
| 32.1 | Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |||||||||||||
| 32.2 | Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |||||||||||||
| 101.INS | The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document | |||||||||||||
| 101.SCH | XBRL Schema Document | |||||||||||||
| 101.CAL | XBRL Calculation Linkbase Documents | |||||||||||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |||||||||||||
| 101.LAB | XBRL Labels Linkbase Documents | |||||||||||||
| 101.PRE | XBRL Presentation Linkbase Documents | |||||||||||||
30
Table of Content
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ANGIODYNAMICS, INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | October 2, 2025 | / S / JAMES C. CLEMMER | ||||||||||||
James C. Clemmer, President, Chief Executive Officer (Principal Executive Officer) | ||||||||||||||
| Date: | October 2, 2025 | / S / STEPHEN A. TROWBRIDGE | ||||||||||||
| Stephen A. Trowbridge, Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) | ||||||||||||||
31
FAQ
What were AngioDynamics (ANGO) net sales and year-over-year growth in Q1 FY2026?
Net sales were $75.7 million, an increase of 12.2% versus the prior-year quarter.
Did AngioDynamics (ANGO) report a profit in Q1 FY2026?
No. The company reported a net loss of $10.9 million, an improvement from a $12.8 million loss in the prior-year quarter.
How much liquidity is available under AngioDynamics's (ANGO) credit facility?
The company has a $25.0 million secured revolving credit facility and had drawn as of August 31, 2025.
What are the material litigation or settlement items disclosed by AngioDynamics (ANGO)?
A settlement with BD requires lump-sum and annual minimum payments ($2.5M paid this quarter) and a contingent $3.0M may be due depending on the Federal Circuit appeal (oral argument Oct 8, 2025). The company is also defending about 219 Port Product Claims.
What restructuring charges did AngioDynamics (ANGO) record?
The company recorded $2.3 million of restructuring charges in the quarter and has recorded $25.6 million of restructuring charges to date.
Angiodynamics
NASDAQ:ANGO
ANGO Rankings
ANGO Latest News
ANGO Latest SEC Filings
Oct 2, 2025
[8-K] ANGIODYNAMICS INC Reports Material Event
Aug 14, 2025
[SCHEDULE 13G/A] AngioDynamics, Inc. SEC Filing
Aug 13, 2025
[SCHEDULE 13G/A] AngioDynamics, Inc. SEC Filing
ANGO Stock Data
482.23M
38.09M
6.84%
93.83%
7.39%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
LATHAM